Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MASSACHUSETTS ANTI-TAKEOVER BILL APPROVED BY BOTH HOUSES

Executive Summary

MASSACHUSETTS ANTI-TAKEOVER BILL APPROVED BY BOTH HOUSES of the state legislature. The measure, which would make hostile takeovers of state companies more difficult, is expected to be signed by Governor Michael Dukakis (D) shortly. The bill had the backing of several Massachusetts-based companies and groups, including Gllette, Polaroid and the state's AFL/CIO. Called the "Massachusetts Control Share Acquisition Law," the legislation would deny anyone who buys, or offers to buy, 20% of the shares in a company the right to vote on those shares. The proposed Massachusetts law would not apply if disinterested holders -- those not affiliated with the acquiring party or the management of the target company -- decide to allow the shares to be voted. In addition, after a target company receives notice from the holder of a 20% block, it would have 50 days to hold a special stockholders' meeting to consider whether those shares should have voting power. Unlike Indiana's anti-takeover act, on which it is modeled, the Massachusetts bill applies both to companies incorporated in the state and those with substantial operations in Massachusetts. The latter provision applies to companies with executive offices in Massachusetts, companies with the bulk of their workforce or assets in the state or at least 10% of their shares owned by state residents (excluding shares held by brokers or nominees). The provision also applies to companies that have 10% of their shareholders living in the state.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS012206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel